The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback